Pharmacogenetic screening for drug therapy:  from single gene markers to decision making in the next generation sequencing era.
Pharmacogenetics has substantially added to our understanding of the variability of drug response. A number of single gene markers have been established and are ready to use in clinical practice. Here we review the validity and utility of markers in a number of genes (CYP2D6, CYP2C19, CYP2C9, VKORC1, TPMT, UGT1A1, OATP1B1, KRAS and HLA locus) for therapy decisions. As drug response is a complex trait in the majority of cases, most of the identified functional variants will only explain a limited part of the variability of drug response. In this sense, a phenotype is the product of many low-penetrance variations. Technical progress has not only improved the cost-effectiveness of screening for single gene markers, but offers the possibility of generating vast amounts of genome-wide single nucleotide polymorphism (SNP) or sequence data for each patient. The latest challenge is to incorporate these amounts of data into pharmacogenetic decision support. We discuss here the challenges associated with choosing the correct therapy for patients who present to their physicians with personal genome data.
Department of Clinical Pharmacology, University Medical Center, Göttingen, Germany.
Mladen
M
Tzvetkov
Nicolas
N
von Ahsen
D015415:Biomarkers / Q000032:analysis; D004358:Drug Therapy / Q000379:methods*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D010597:Pharmacogenetics / Q000379:methods*
D015415:Biomarkers